Compare Incyte Corporation (INCY) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Block Inc — how do they compare? Incyte Corporation trades at $118.05 (market cap $23.11B), while Block Inc trades at $80.11 (market cap $47.19B). The key difference: Block Inc is far larger — about 2× Incyte Corporation's market cap. Which is the better fit depends on your goals.
| INCY | XYZ | |
|---|---|---|
Market Cap | $23.11B | $47.19B |
Sector | Health | Technology |
52-Week High | $118.52 | $81.81 |
52-Week Low | $67.38 | $49.04 |
Enterprise Value | $19.13B | $42.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Block (XYZ) trades at $79.72, down 0.28% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company reported mixed Q1 2026 earnings, beating expectations with $0.85 EPS versus $0.675 forecast, while revenue reached $24.19 billion in 2025. Recent news highlights include a $45 million settlement over Cash App fraud allegations and continued strength in Square and Cash App segments.
The stock offers 12% upside to the $89.53 consensus price target, supported by 74% analyst buy ratings. However, elevated P/E of 62.45 and declining net income margins from 12.01% to 5.39% pose valuation concerns. Key risks include rising credit losses and regulatory scrutiny, while AI integration and payment growth present long-term opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
